GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Harvard Bioscience Inc (NAS:HBIO) » Definitions » Cash Flow from Investing

Harvard Bioscience (Harvard Bioscience) Cash Flow from Investing : $-1.8 Mil (TTM As of Dec. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Harvard Bioscience Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Dec. 2023, Harvard Bioscience spent $0.8 Mil on purchasing property, plant, equipment. It gained $0.0 Mil from selling property, plant, and equipment. It spent $0.0 Mil on purchasing business. It gained $0.0 Mil from selling business. It spent $0.0 Mil on purchasing investments. It gained $0.0 Mil from selling investments. It paid $0.0Mil for net Intangibles purchase and sale. And it paid $0.2 Mil for other investing activities. In all, Harvard Bioscience spent $1.1 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Dec. 2023.


Harvard Bioscience Cash Flow from Investing Historical Data

The historical data trend for Harvard Bioscience's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Harvard Bioscience Cash Flow from Investing Chart

Harvard Bioscience Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.23 -1.40 -1.35 -1.59 -1.80

Harvard Bioscience Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.24 0.29 -0.63 -0.40 -1.06

Harvard Bioscience Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Harvard Bioscience's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:

Harvard Bioscience's Cash Flow from Investing for the quarter that ended in Dec. 2023 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Harvard Bioscience  (NAS:HBIO) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Harvard Bioscience's purchase of property, plant, equipment for the three months ended in Dec. 2023 was $-0.8 Mil. It means Harvard Bioscience spent $0.8 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Harvard Bioscience's sale of property, plant, equipment for the three months ended in Dec. 2023 was $0.0 Mil. It means Harvard Bioscience gained $0.0 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Harvard Bioscience's purchase of business for the three months ended in Dec. 2023 was $0.0 Mil. It means Harvard Bioscience spent $0.0 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Harvard Bioscience's sale of business for the three months ended in Dec. 2023 was $0.0 Mil. It means Harvard Bioscience gained $0.0 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Harvard Bioscience's purchase of investment for the three months ended in Dec. 2023 was $0.0 Mil. It means Harvard Bioscience spent {stock_data.stock.currency_symbol}}0.0 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Harvard Bioscience's sale of investment for the three months ended in Dec. 2023 was $0.0 Mil. It means Harvard Bioscience gained $0.0 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Harvard Bioscience's net Intangibles purchase and sale for the three months ended in Dec. 2023 was $0.0 Mil. It means Harvard Bioscience paid $0.0 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Harvard Bioscience's cash from discontinued investing activities for the three months ended in Dec. 2023 was 0.0 Mil. It means Harvard Bioscience paid $0.0 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Harvard Bioscience's cash from other investing activities for the three months ended in Dec. 2023 was $-0.2 Mil. It means Harvard Bioscience paid $0.2 Mil for other investing activities.


Harvard Bioscience Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Harvard Bioscience's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Harvard Bioscience (Harvard Bioscience) Business Description

Traded in Other Exchanges
Address
84 October Hill Road, Holliston, MA, USA, 01746
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life science and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab.. The majority of its revenue comes from the United States.
Executives
James W Green director, officer: Chief Executive Officer 12525 CHADRON AVENUE, HAWTHORNE CA 90250
Alan I Edrick director 20200 SUNBURST STREET, CHATSWORTH CA 91311
Jennifer Cote officer: Interim CFO C/O HARVARD BIOSCIENCE, INC., 84 OCTOBER HILL ROAD, HOLLISTON MA 01746
Bertrand Loy director C/O ENTEGRIS, INC., 129 CONCORD RD, BILLERICA MA 01821
Thomas W Loewald director 81 WYMAN STREET, WALTHAM MA 02451
John F Kennedy director C/O NET PERCEPTIONS INC, 7700 FRANCE AVE. SOUTH, EDINA MN 55435
Katherine A. Eade director C/O HARVARD BIOSCIENCE, INC., 84 OCTOBER HILL ROAD #10, HOLLISTON MA 01746
Susan M. Steele director C/O HILL INTERNATIONAL, INC., 2005 MARKET ST., 17TH FLOOR, PHILADELPHIA PA 19103
Kenneth Fletcher Olson officer: Chief Operating Officer C/O HARVARD BIOSCIENCE, INC., 84 OCTOBER HILL ROAD #10, HOLLISTON MA 01746
Michael A. Rossi officer: Chief Financial Officer C/O HARVARD BIOSCIENCE, INC., 84 OCTOBER HILL ROAD #10, HOLLISTON MA 01746
Yash Singh officer: Executive Vice President C/O HARVARD BIOSCIENCE, INC., 84 OCTOBER HILL ROAD #10, HOLLISTON MA 01746
Jeffrey Duchemin officer: Chief Executive Officer 14 EASTLAND TERRACE, HAVERHILL MA 01830
Kamalam Unninayar officer: Chief Financial Officer C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472
Robert E. Gagnon officer: Chief Financial Officer C/O BIOGEN IDEC INC., 133 BOSTON POST ROAD, WESTON MA 02493
George Uveges director C/O MFIC CORPORATION, 30 OSSIPEE ROAD, NEWTON MA 02464